Cargando…
Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers
Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1 (ASS1) that is necessary for synthesis of L-arginine. These cancers must import arginine for survival and growth, and this reliance can be targeted by arginine-degrading extracellular enzymatic drugs, most commonly...
Autores principales: | Rogers, Leonard C., Van Tine, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992531/ https://www.ncbi.nlm.nih.gov/pubmed/35582579 http://dx.doi.org/10.20517/cdr.2019.49 |
Ejemplares similares
-
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022) -
Intracellular arginine-dependent translation sensor reveals the dynamics of arginine starvation response and resistance in ASS1-negative cells
por: Rogers, Leonard C., et al.
Publicado: (2021) -
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
por: Bean, Gregory R, et al.
Publicado: (2016) -
Arginine deprivation therapy for malignant melanoma
por: Yoon, Jung-Ki, et al.
Publicado: (2012) -
Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
por: Sun, Naihui, et al.
Publicado: (2022)